Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2⁺ Breast Cancer

Cancer Res (2024) 84 (5): 675–687.

https://doi.org/10.1158/0008-5472.CAN-23-1459

Published: 04 March 2024

View articletitled, AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract 3445: Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy

Fabiana Napolitano, Dhivya R. Sudhan, Yunguan Wang, Paula I. González-Ericsson, Luigi Formisano, Kyung-Min Lee, Chang-Ching Lin, María Rosario Chica-Parrado, Hongli Ma, Nathaniel Evans, Alberto Servetto, Saurabh Mendiratta, Spencer Barnes, Yisheng V. Fang, Justin M. Balko, Gordon B. Mills, Marilyne Labrie, Ariella B. Hanker, Carlos L. Arteaga

Cancer Res (2023) 83 (7_Supplement): 3445.

https://doi.org/10.1158/1538-7445.AM2023-3445

Published: 04 April 2023

View articletitled, Abstract 3445: Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy

Journal Articles

Abstract 2726: Host myeloid response drives anti-PD-L1 resistance in murine models of triple negative breast cancer

Ann Hanna, Xiaopeng Sun, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Justin M. Balko

Cancer Res (2022) 82 (12_Supplement): 2726.

https://doi.org/10.1158/1538-7445.AM2022-2726

Published: 15 June 2022

View articletitled, Abstract 2726: Host myeloid response drives anti-PD-L1 resistance in murine models of triple negative breast cancer

Journal Articles

Abstract PD3-04: Multi-omics characterization of triple-negative breast cancer identifies therapeutic vulnerabilities and epigenetic immune suppression in the mesenchymal subtype

Brian D Lehmann, Antonio Colaprico, Tiago C Silva, Jianjiao Chen, Hanbing An, Yuguang Ban, Lily Wang, Jamaal L James, Justin Balko, Paula I Gonzalez-Ericsson, Melinda E Sanders, Bing Zhang, Jennifer A Pietenpol, Xi S Chen

Cancer Res (2022) 82 (4_Supplement): PD3-04.

https://doi.org/10.1158/1538-7445.SABCS21-PD3-04

Published: 15 February 2022

View articletitled, Abstract PD3-04: Multi-omics characterization of triple-negative breast cancer identifies therapeutic vulnerabilities and epigenetic immune suppression in the mesenchymal subtype

Journal Articles

Abstract P1-08-34: Peripheral immunity predicts therapeutic outcomes in breast cancer patients

Margaret L Axelrod, Yu Wang, Yaomin Xu, Cosmin A. Bejan, Xiaopeng Sun, Paula I Gonzalez-Ericsson, Riley E Bergman, Joshua Donaldson, Sara Nunnery, Melinda Sanders, Chiara Massa, Barbara Seliger, Ingrid A Mayer, Justin M Balko

Cancer Res (2022) 82 (4_Supplement): P1-08-34.

https://doi.org/10.1158/1538-7445.SABCS21-P1-08-34

Published: 15 February 2022

View articletitled, Abstract P1-08-34: Peripheral immunity predicts therapeutic outcomes in breast cancer patients

Journal Articles

Abstract P1-04-03: Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1

Ann Hanna, Xiaopeng Sun, Paula I. Gonzalez-Ericsson, Violeta M. Sanchez, Melinda E. Sanders, Justin M. Balko

Cancer Res (2022) 82 (4_Supplement): P1-04-03.

https://doi.org/10.1158/1538-7445.SABCS21-P1-04-03

Published: 15 February 2022

View articletitled, Abstract P1-04-03: Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1

Journal Articles

Abstract PS17-14: Evaluating the efficacy of immunotherapy in triple negative breast cancer

Ann Hanna, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Melinda E. Sanders, Justin M. Balko

Cancer Res (2021) 81 (4_Supplement): PS17-14.

https://doi.org/10.1158/1538-7445.SABCS20-PS17-14

Published: 15 February 2021

View articletitled, Abstract PS17-14: Evaluating the efficacy of immunotherapy in triple negative breast cancer

Journal Articles

Abstract PD9-06: Peripheral blood gene signatures predict response to neoadjuvant chemotherapy in breast cancer patients

Margaret L Axelrod, Paula I Gonzalez-Ericsson, Xiaopeng Sun, Riley E Bergman, Joshua Donaldson, Sara M Tolaney, Ian E Krop, Ana C Garrido-Castro, Melinda E. Sanders, Ingrid A Mayer, Justin M Balko

Cancer Res (2021) 81 (4_Supplement): PD9-06.

https://doi.org/10.1158/1538-7445.SABCS20-PD9-06

Published: 15 February 2021

View articletitled, Abstract PD9-06: Peripheral blood gene signatures predict response to neoadjuvant chemotherapy in breast cancer patients

Journal Articles

Abstract P3-08-15: Immunologic correlates of long-term outcome in the residual disease of triple-negative breast cancer after neoadjuvant chemotherapy

Justin M Balko, Mellissa Nixon, Paula I Gonzalez-Ericsson, Mark A Pilkinton, Wyatt J McDonnell, Violeta Sanchez, Susan R Opalenik, Sherene Loi, Brent Rexer, Vandana Abramson, Valerie Jansen, Simon Mallal, Jonathan D Marotti, Kevin Shee, Todd W Miller, Melinda E Sanders, Ingrid A Mayer, Roberto Salgado

Cancer Res (2020) 80 (4_Supplement): P3-08-15.

https://doi.org/10.1158/1538-7445.SABCS19-P3-08-15

Published: 15 February 2020

View articletitled, Abstract P3-08-15: Immunologic correlates of long-term outcome in the residual disease of triple-negative breast cancer after neoadjuvant chemotherapy

Journal Articles

Abstract PD5-07: The immune landscape of residual triple-negative breast cancers after neoadjuvant chemotherapy

Paula I Gonzalez-Ericsson, Violeta Sanchez, Roberto Salgado, Jennifer Bordeaux, Ju Y Kim, Christine Vaupel, Henry Gomez, Melinda E Sanders, Justin M Balko

Cancer Res (2020) 80 (4_Supplement): PD5-07.

https://doi.org/10.1158/1538-7445.SABCS19-PD5-07

Published: 15 February 2020

View articletitled, Abstract PD5-07: The immune landscape of residual triple-negative breast cancers after neoadjuvant chemotherapy

Journal Articles

Abstract 4978: Digital spatial profiling of molecular responses to nanoparticle STING agonists identify S100A9 and B7-H3 as possible escape mechanisms

John T. Wilson, Daniel Shae, Paula I. Gonzalez-Ericsson, Violeta Sanchez, JingJing Gong, Yan Liang, Douglas Hinerfeld, Joseph M. Beechem, Justin M. Balko

Cancer Res (2019) 79 (13_Supplement): 4978.

https://doi.org/10.1158/1538-7445.AM2019-4978

Published: 01 July 2019

View articletitled, Abstract 4978: Digital spatial profiling of molecular responses to nanoparticle STING agonists identify S100A9 and B7-H3 as possible escape mechanisms

Journal Articles

Abstract 4050: Molecular characterization of residual triple-negative breast cancers after neoadjuvant chemotherapy identifies immune composition and features associated with clinical outcome

Caroline Nebhan, Paula I. Gonzalez-Ericsson, Roberto Salgado, Jennifer Bordeaux, Ju Young Kim, Christine Vaupel, Henry Gomez, Justin Micah Balko

Cancer Res (2019) 79 (13_Supplement): 4050.

https://doi.org/10.1158/1538-7445.AM2019-4050

Published: 01 July 2019

View articletitled, Abstract 4050: Molecular characterization of residual triple-negative breast cancers after neoadjuvant chemotherapy identifies immune composition and features associated with clinical outcome

Journal Articles

Abstract LB-056: Quantitative mass spectrometry analysis of immune checkpoint protein expression and N-glycosylation in human melanoma

Carlos Morales Betanzos, Hyoungjoo Lee, Paula I. Gonzalez Ericsson, Justin M. Balko, Douglas B. Johnson, Lisa J. Zimmerman, Daniel C. Liebler

Cancer Res (2017) 77 (13_Supplement): LB-056.

https://doi.org/10.1158/1538-7445.AM2017-LB-056

Published: 01 July 2017

View articletitled, Abstract LB-056: Quantitative mass spectrometry analysis of immune checkpoint protein expression and N-glycosylation in human melanoma

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2⁺ Breast Cancer

Abstract 3445: Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy

Abstract 2726: Host myeloid response drives anti-PD-L1 resistance in murine models of triple negative breast cancer

Abstract PD3-04: Multi-omics characterization of triple-negative breast cancer identifies therapeutic vulnerabilities and epigenetic immune suppression in the mesenchymal subtype

Abstract P1-08-34: Peripheral immunity predicts therapeutic outcomes in breast cancer patients

Abstract P1-04-03: Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1

Abstract PS17-14: Evaluating the efficacy of immunotherapy in triple negative breast cancer

Abstract PD9-06: Peripheral blood gene signatures predict response to neoadjuvant chemotherapy in breast cancer patients

Abstract P3-08-15: Immunologic correlates of long-term outcome in the residual disease of triple-negative breast cancer after neoadjuvant chemotherapy

Abstract PD5-07: The immune landscape of residual triple-negative breast cancers after neoadjuvant chemotherapy

Abstract 4978: Digital spatial profiling of molecular responses to nanoparticle STING agonists identify S100A9 and B7-H3 as possible escape mechanisms

Abstract 4050: Molecular characterization of residual triple-negative breast cancers after neoadjuvant chemotherapy identifies immune composition and features associated with clinical outcome

Abstract LB-056: Quantitative mass spectrometry analysis of immune checkpoint protein expression and N-glycosylation in human melanoma

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only